PledPharma is a Swedish pharmaceutical company developing new drugs that protect the body against oxidative stress – a potentially disabling and sometimes life-threatening condition that can be caused by for example chemotherapy treatment or acetaminophen (paracetamol) overdose. The company’s most advanced project PledOx® reduces nerve damage associated with chemotherapy treatment. Positive results from phase IIb study PLIANT were presented in the spring of 2015 with follow-up and survival data presented during 2016. Phase III studies are planned to start during 2017. The drug candidate Aladote® is developed to reduce the risk of acute liver failure associated with acetaminophen overdose. Proof-of-principle clinical studies are planned to start 2017.
PledPharma (STO:PLED) is listed on Nasdaq First North